Aims Diabetes mellitus (DM) is one of the most important cardiovascular risk factors. The aim of this study was to evaluate clinical correlates of DM, including management and outcomes, in the EURObservational Research Programme (EORP)-Atrial Fibrillation (AF) General Pilot (EORP-AF) Registry of the European Society of Cardiology. Methods and results We studied consecutive patients (N= 3101) enrolled in 70 centres of nine European countries between February 2012 and March 2013, and compared diabetics with non-diabetics during a 1-year follow-up. In the overall cohort, the prevalence of DM was 20.6%. Diabetics were older (71 ± 9 vs. 68 ± 12 years, P < 0.0001) and had more comorbidities, higher CHA2DS2-VASc score (4.6 ± 1.6 vs. 2.9 ± 1.7, P < 0.0001) and higher prevalence of permanent AF (21.5 vs. 16.0%, P = 0.0022). Quality of life amongst DM patients was significantly worse [atrial fibrillation quality of life questionnaire (AF-QoL) score 45.2 ± 19.2 vs. 49.3 ± 20.1, P < 0.0001]. Amongst diabetics, the use of electrical cardioversion (16.2 vs. 24.6%, P < 0.0001) and catheter ablation (3.3 vs. 8.6%, P < 0.0001) was lower, whilst oral anticoagulants were more often prescribed (84.3 vs. 78.9%, P = 0.0027). After one year, diabetic patients had significantly higher all-cause (11.9 vs. 4.9%, P < 0.0001), cardiovascular (6.2 vs. 1.9%, P < 0.0001), and non-cardiovascular mortality (2.3 vs. 1.1%, P = 0.0356). Conclusion In AF patients, DM is associated with a higher prevalence of comorbidities and a worse quality of life. After one year, all-cause, cardiovascular, and non-cardiovascular mortality were significantly higher in diabetic subjects.

Management and prognosis of atrial fibrillation in diabetic patients: An EORP-AF General Pilot Registry report / Fumagalli, Stefano; Said, Salah A.; Laroche, Cecile; Gabbai, Debbie; Boni, Serena; Marchionni, Niccolò; Boriani, Giuseppe; Maggioni, Aldo P.; Musialik-Lydka, Agata; Sokal, Adam; Petersen, Jens; Crijns, Harry J. G. M; Lip, Gregory Y. H.. - In: EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY. - ISSN 2055-6837. - 4:3(2018), pp. 172-179.

Management and prognosis of atrial fibrillation in diabetic patients: An EORP-AF General Pilot Registry report

Boriani, Giuseppe;
2018

Abstract

Aims Diabetes mellitus (DM) is one of the most important cardiovascular risk factors. The aim of this study was to evaluate clinical correlates of DM, including management and outcomes, in the EURObservational Research Programme (EORP)-Atrial Fibrillation (AF) General Pilot (EORP-AF) Registry of the European Society of Cardiology. Methods and results We studied consecutive patients (N= 3101) enrolled in 70 centres of nine European countries between February 2012 and March 2013, and compared diabetics with non-diabetics during a 1-year follow-up. In the overall cohort, the prevalence of DM was 20.6%. Diabetics were older (71 ± 9 vs. 68 ± 12 years, P < 0.0001) and had more comorbidities, higher CHA2DS2-VASc score (4.6 ± 1.6 vs. 2.9 ± 1.7, P < 0.0001) and higher prevalence of permanent AF (21.5 vs. 16.0%, P = 0.0022). Quality of life amongst DM patients was significantly worse [atrial fibrillation quality of life questionnaire (AF-QoL) score 45.2 ± 19.2 vs. 49.3 ± 20.1, P < 0.0001]. Amongst diabetics, the use of electrical cardioversion (16.2 vs. 24.6%, P < 0.0001) and catheter ablation (3.3 vs. 8.6%, P < 0.0001) was lower, whilst oral anticoagulants were more often prescribed (84.3 vs. 78.9%, P = 0.0027). After one year, diabetic patients had significantly higher all-cause (11.9 vs. 4.9%, P < 0.0001), cardiovascular (6.2 vs. 1.9%, P < 0.0001), and non-cardiovascular mortality (2.3 vs. 1.1%, P = 0.0356). Conclusion In AF patients, DM is associated with a higher prevalence of comorbidities and a worse quality of life. After one year, all-cause, cardiovascular, and non-cardiovascular mortality were significantly higher in diabetic subjects.
22-dic-2017
4
3
172
179
Management and prognosis of atrial fibrillation in diabetic patients: An EORP-AF General Pilot Registry report / Fumagalli, Stefano; Said, Salah A.; Laroche, Cecile; Gabbai, Debbie; Boni, Serena; Marchionni, Niccolò; Boriani, Giuseppe; Maggioni, Aldo P.; Musialik-Lydka, Agata; Sokal, Adam; Petersen, Jens; Crijns, Harry J. G. M; Lip, Gregory Y. H.. - In: EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY. - ISSN 2055-6837. - 4:3(2018), pp. 172-179.
Fumagalli, Stefano; Said, Salah A.; Laroche, Cecile; Gabbai, Debbie; Boni, Serena; Marchionni, Niccolò; Boriani, Giuseppe; Maggioni, Aldo P.; Musialik-Lydka, Agata; Sokal, Adam; Petersen, Jens; Crijns, Harry J. G. M; Lip, Gregory Y. H.
File in questo prodotto:
File Dimensione Formato  
pvx037.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 339.6 kB
Formato Adobe PDF
339.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1167964
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact